Catalina Capital Group LLC Purchases New Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Catalina Capital Group LLC acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 26,593 shares of the company’s stock, valued at approximately $82,000.

A number of other institutional investors also recently bought and sold shares of the business. State Street Corp grew its holdings in shares of Tango Therapeutics by 26.8% during the third quarter. State Street Corp now owns 2,318,208 shares of the company’s stock worth $17,850,000 after buying an additional 489,949 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Tango Therapeutics by 11.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after purchasing an additional 142,710 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Tango Therapeutics by 18.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,237 shares of the company’s stock valued at $3,752,000 after purchasing an additional 76,540 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Tango Therapeutics by 42.5% in the second quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after purchasing an additional 100,257 shares during the period. Finally, Walleye Capital LLC purchased a new stake in shares of Tango Therapeutics during the third quarter worth approximately $1,098,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TNGX has been the topic of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Guggenheim dropped their price target on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. B. Riley reduced their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Friday, November 8th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has an average rating of “Buy” and a consensus price target of $13.14.

Insider Activity at Tango Therapeutics

In related news, Director Mace Rothenberg bought 10,000 shares of the stock in a transaction on Monday, November 18th. The shares were purchased at an average price of $3.78 per share, for a total transaction of $37,800.00. Following the acquisition, the director now owns 31,250 shares in the company, valued at $118,125. This represents a 47.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.30% of the stock is currently owned by company insiders.

Tango Therapeutics Trading Up 4.5 %

Shares of Tango Therapeutics stock opened at $3.04 on Wednesday. The company has a 50-day moving average of $3.17 and a two-hundred day moving average of $6.19. The stock has a market cap of $326.56 million, a PE ratio of -2.58 and a beta of 0.80. Tango Therapeutics, Inc. has a 12-month low of $2.59 and a 12-month high of $12.89.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.